Ads
related to: pathology outlines markers for cancer centers list
Search results
Results From The WOW.Com Content Network
It is therefore used as a marker of carcinomas, such as depth of invasion and metastases. [1] For example, it is both relatively sensitive and specific for detection of breast cancer metastasis to sentinel lymph nodes. [3] It may cross-react with GFAP, leading to aberrant staining of glial tumors such as ependymoma, glioblastoma and schwannoma. [1]
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor ...
A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule." [18] In cancer research and medicine, biomarkers are used in three primary ways: [19] To help diagnose conditions, as in the case of identifying early stage cancers (diagnostic)
A tingible body macrophage (TBM) is a type of macrophage predominantly found in germinal centers of lymph nodes. They contain many phagocytized, apoptotic cells in various states of degradation, referred to as tingible bodies (tingible meaning stainable). [2] Tingible body macrophages contain condensed chromatin fragments. [3]
A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring . [ 1 ]
Grading in cancer is distinguished from staging, which is a measure of the extent to which the cancer has spread. Pathology grading systems classify the microscopic cell appearance abnormality and deviations in their rate of growth with the goal of predicting developments at tissue level (see also the 4 major histological changes in dysplasia ).
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]
Several members of the S100 protein family are useful as markers for certain tumors and epidermal differentiation. They can be found in melanomas , [ 8 ] 100% of schwannomas , 100% of neurofibromas (weaker than schwannomas), 50% of malignant peripheral nerve sheath tumors (may be weak and/or focal), paraganglioma stromal cells, histiocytoma ...